Concord Drugs Ltd
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on
approved formulations
- Market Cap ₹ 36.0 Cr.
- Current Price ₹ 36.0
- High / Low ₹ 61.5 / 30.6
- Stock P/E
- Book Value ₹ 33.9
- Dividend Yield 0.00 %
- ROCE 5.01 %
- ROE 1.45 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.06 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -1.02%
- Company has high debtors of 161 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|
58.96 | 52.08 | 44.92 | 52.48 | |
53.37 | 47.51 | 40.88 | 49.79 | |
Operating Profit | 5.59 | 4.57 | 4.04 | 2.69 |
OPM % | 9.48% | 8.77% | 8.99% | 5.13% |
0.10 | 0.01 | 0.01 | 0.00 | |
Interest | 1.68 | 1.71 | 1.87 | 1.92 |
Depreciation | 1.76 | 1.63 | 1.56 | 1.46 |
Profit before tax | 2.25 | 1.24 | 0.62 | -0.69 |
Tax % | 28.89% | 20.97% | 25.81% | |
1.59 | 0.99 | 0.47 | -0.51 | |
EPS in Rs | 1.82 | 1.06 | 0.47 | -0.51 |
Dividend Payout % | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 24% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -131% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 6% |
1 Year: | 4% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 8.74 | 9.32 | 10.00 | 10.00 |
Reserves | 19.62 | 21.82 | 23.82 | 23.88 |
16.43 | 16.96 | 17.52 | 19.09 | |
11.66 | 10.13 | 7.47 | 20.29 | |
Total Liabilities | 56.45 | 58.23 | 58.81 | 73.26 |
13.97 | 12.92 | 11.68 | 11.04 | |
CWIP | 0.55 | 0.92 | 1.63 | 1.78 |
Investments | 0.00 | 0.89 | 0.84 | 0.84 |
41.93 | 43.50 | 44.66 | 59.60 | |
Total Assets | 56.45 | 58.23 | 58.81 | 73.26 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
0.77 | 1.66 | 0.79 | |
-2.44 | -2.27 | -1.01 | |
1.68 | 0.62 | 0.28 | |
Net Cash Flow | 0.01 | 0.02 | 0.07 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
Debtor Days | 141.52 | 110.80 | 161.13 |
Inventory Days | 151.64 | 178.58 | 251.53 |
Days Payable | 62.25 | 46.92 | 37.75 |
Cash Conversion Cycle | 230.90 | 242.47 | 374.91 |
Working Capital Days | 198.84 | 252.16 | 317.30 |
ROCE % | 6.35% | 5.01% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Copy of News Paper publication for quarter results ending September 30, 2024.
- Financial Results For Q2 Ending Sep 30, 2024 13 Nov
-
Board Meeting Outcome for Financial Results For Quarter Ended 30 September 2024
13 Nov - Approved un-audited financial results for Q2 2024.
-
Board Meeting Intimation for Quarterly Results For 30 September, 2024
6 Nov - Board meeting scheduled to approve Q2 financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21 Oct - Certificate under Regulation 74(5) of SEBI submitted.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Product Portfolio:[1]
a) Pharmaceutical Ready to fill Pellets
b) Multiple Unit Pellet System (MUPS)
c) Tissue Bio Adhesive
d) Injectables (Small Volume Parenterals)
e) Oral Solid Dosages (Tablets & Capsules)
f) Liquid Orals (Syrups & Suspensions)
g) Dry Syrup (Powder)